These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1147 related articles for article (PubMed ID: 9408699)

  • 41. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
    Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA
    Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Ganciclovir prophylaxis for cytomegalovirus interstitial pneumonitis after allogeneic bone marrow transplantation].
    Sakai R; Maruta A; Taguchi J; Tomita N; Fujita H; Kodama F; Ogawa K; Fujisawa S; Matsuzaki M; Motomura S; Okubo T
    Rinsho Ketsueki; 1996 Jan; 37(1):14-21. PubMed ID: 8683862
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytomegalovirus-specific CD8+ T cells do not develop in all renal transplant patients at risk of virus infection.
    Christmas SE; Halliday D; Lawton N; Wang H; Abdalla I; Masters J; Hassan RL; Hart IJ; Khan N; Smith J; Hammad A; Bakran A
    Transpl Immunol; 2009 Dec; 22(1-2):99-104. PubMed ID: 19635559
    [TBL] [Abstract][Full Text] [Related]  

  • 44. "Refractoriness" of airflow obstruction associated with isolated lymphocytic bronchiolitis/bronchitis in pulmonary allografts.
    Ross DJ; Marchevsky A; Kramer M; Kass RM
    J Heart Lung Transplant; 1997 Aug; 16(8):832-8. PubMed ID: 9286775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of higher dose and lower dose ganciclovir for cytomegalovirus prophylaxis in seropositive heart transplant recipients.
    Lee SO; Rim JH; Sung H; Kim SH; Choi SH; Lee CW; Yun TJ; Lee JW; Woo JH; Kim YS; Kim JJ
    Transpl Infect Dis; 2010 Feb; 12(1):31-7. PubMed ID: 19843292
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
    Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Historical comparison of prophylactic ganciclovir for gastrointestinal cytomegalovirus infection in kidney transplant recipients.
    Kim HC; Hwang EA; Park SB; Kim HT; Cho WH
    Transplant Proc; 2012 Apr; 44(3):710-2. PubMed ID: 22483474
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Prevention of cytomegalovirus infection following heart transplantation].
    Laske A; Carrel T; Niederhäuser U; Bauer E; Pasic M; von Segesser LK; Gallino A; Turina M
    Helv Chir Acta; 1992 Jan; 58(4):527-32. PubMed ID: 1316336
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Viral prophylaxis in combined pancreas-kidney transplant recipients.
    Stratta RJ; Taylor RJ; Bynon JS; Lowell JA; Cattral MS; Frisbie K; Miller S; Radio SJ; Brennan DC
    Transplantation; 1994 Feb; 57(4):506-12. PubMed ID: 8116033
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
    von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D
    Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Should heart-lung transplant donors and recipients be matched according to cytomegalovirus serologic status?
    Novick RJ; Menkis AH; McKenzie FN; Reid KR; Ahmad D
    J Heart Transplant; 1990; 9(6):699-706. PubMed ID: 2177496
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful management of symptomatic cytomegalovirus disease with ganciclovir after heart transplantation.
    Cooper DK; Novitzky D; Schlegel V; Muchmore JS; Cucchiara A; Zuhdi N
    J Heart Lung Transplant; 1991; 10(5 Pt 1):656-62; discussion 662-3. PubMed ID: 1659901
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection.
    Winston DJ; Imagawa DK; Holt CD; Kaldas F; Shaked A; Busuttil RW
    Transplantation; 1995 Dec; 60(11):1357-60. PubMed ID: 8525537
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The influence of cytomegalovirus infections on patient and renal graft outcome: a 3-year, multicenter, observational study (Post-ECTAZ Study).
    Abou-Ayache R; Büchler M; Le Pogamp P; Westeel PF; Le Meur Y; Etienne I; Hurault de Ligny B; Toupance O; Caillard S; Sinnasse-Raymond G; Touchard G
    Transplant Proc; 2011 Sep; 43(7):2630-5. PubMed ID: 21911136
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
    Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S
    Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Post-renal transplant cytomegalovirus infection: study of risk factors.
    Kute VB; Vanikar AV; Shah PR; Gumber MR; Patel HV; Godara SM; Munjappa BC; Sainaresh VV; Engineer DP; Jain SH; Modi PR; Shah VR; Trivedi VB; Trivedi HL
    Transplant Proc; 2012 Apr; 44(3):706-9. PubMed ID: 22483473
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Cytomegalovirus in liver transplantation: incidence and groups at risk].
    Schiffer V; Mentha G; Giostra E; Belli D; Le Coultre C; Rohner A
    Schweiz Med Wochenschr; 1994 Apr; 124(15):631-6. PubMed ID: 8191266
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prophylaxis against herpes infections in kidney transplant patients with special emphasis on CMV.
    Birkeland SA; Andersen HK; Gahrn-Hansen B
    Scand J Infect Dis; 1998; 30(3):221-6. PubMed ID: 9790127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.